What Researchers Did
Researchers studied 60 chronic hepatitis patients, giving one group hyperbaric oxygen therapy for six courses and the other standard medication for 60 days.
What They Found
The group receiving hyperbaric oxygen therapy showed significant decreases (P < 0.05) in liver enzymes (ALT, SB, gamma-GT, AKP) and immune markers (IgG, IgM) in their blood. They also experienced significant improvements (P < 0.05) in liver blood flow and reduced cellular damage, including less hepatocyte degeneration, necrosis, and inflammation, compared to the control group.
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen therapy might offer a new way to improve liver function and reduce cellular damage in patients with chronic hepatitis. If these findings are confirmed by larger studies, HBOT could potentially become an additional treatment option for managing this condition.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This study involved a relatively small number of patients and was conducted over a limited time, meaning larger and longer-term studies are needed to confirm these findings.